ELECTROPHYSIOLOGICAL AND ARRHYTHMOGENIC EFFECTS OF PLATELET-ACTIVATING-FACTOR DURING NORMAL PERFUSION, MYOCARDIAL-ISCHEMIA AND REPERFUSION IN THE GUINEA-PIG

被引:36
作者
FLORES, NA
SHERIDAN, DJ
机构
[1] Academic Cardiology Unit, St. Mary's Hospital Med. Sch., London W2 1NY, South Wharf Road
关键词
D O I
10.1111/j.1476-5381.1990.tb14149.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Platelet activating factor (PAF) is often used to study the effects of platelet activation. While direct myocardial electrophysiological effects of PAF have been described in superfused myocardial tissue, little is known about its actions on the whole heart. 2. The cellular electrophysiological and arrhythmogenic effects of PAF (10-11 M, 10-10 M and 10-9 M) were studied during normal perfusion, global myocardial ischaemia and reperfusion in Langendorff-perfused guinea-pig hearts at 32°C. 3. PAF (10-9 M) increased the incidence of ventricular fibrillation during ischaemia and reduced action potential duration (APD) during normal perfusion and early myocardial ischaemia (10-9 M and 10-10 M). PAF also reduced refractory period (RP) during normal perfusion (10-9 M) and early ischaemia (10-9 M and 10-10 M). PAF prevented recovery of APD (10-9 M) and RP (10-9 M and 10-10 M) during reperfusion. PAF at a concentration of 10-11 M had no electrophysiological effects. 4. PAF (10-9 M) increased the QRS width of the electrocardiogram during late ischaemia while 10-10 M PAF raised pacing threshold during late ischaemia. 5. Perfusion pressure was increased, and developed tension decreased by 10-9 M PAF. 6. These results demonstrate that PAF has direct myocardial electrophysiological effects in the whole heart which occur during normal perfusion and are capable of augmenting the effects of myocardial ischaemia, but are independent of the presence of platelets.
引用
收藏
页码:734 / 738
页数:5
相关论文
共 36 条
[1]   EFFECT OF PLATELET-ACTIVATING-FACTOR (PAF) ON HUMAN CARDIAC-MUSCLE [J].
ALLOATTI, G ;
MONTRUCCHIO, G ;
MARIANO, F ;
TETTA, C ;
DEPAULIS, R ;
MOREA, M ;
EMANUELLI, G ;
CAMUSSI, G .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1986, 79 (01) :108-112
[2]  
ANNABLE CR, 1985, FED PROC, V44, P1271
[3]   THE EFFECTS OF PAF-ACETHER ON THE CARDIOVASCULAR-SYSTEM AND THEIR INHIBITION BY A NEW HIGHLY SPECIFIC PAF-ACETHER RECEPTOR ANTAGONIST BN 52021 [J].
BARANES, J ;
HELLEGOUARCH, A ;
LEHEGARAT, M ;
VIOSSAT, I ;
AUGUET, M ;
CHABRIER, PE ;
BRAQUET, P ;
BRAQUET, F .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1986, 18 (08) :717-737
[4]   THE ACTIONS OF PAF-ACETHER (PLATELET-ACTIVATING FACTOR) ON GUINEA-PIG ISOLATED HEART PREPARATIONS [J].
BENVENISTE, J ;
BOULLET, C ;
BRINK, C ;
LABAT, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 80 (01) :81-83
[5]   ACUTE CIRCULATORY COLLAPSE CAUSED BY PLATELET-ACTIVATING FACTOR (PAF-ACETHER) IN DOGS [J].
BESSIN, P ;
BONNET, J ;
APFFEL, D ;
SOULARD, C ;
DESGROUX, L ;
PELAS, I ;
BENVENISTE, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 86 (3-4) :403-413
[6]  
BRAQUET P, 1987, PHARMACOL REV, V39, P97
[7]  
CAMUSSI G, 1984, EXPERIENTIA, V40, P607
[8]  
CHAKRABARTY S, 1988, BRIT HEART J, V59, P637
[9]  
CHAKRABARTY S, 1989, CIRCULATION, V80, P233
[10]  
DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355